Angiogenesis inhibitors in the treatment of lung cancer

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

1997 • 4,504 citations

The Biology of Vascular Endothelial Growth Factor

1997 • 4,359 citations

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

1995 • 3,139 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor

1992 • 2,042 citations

Changing views of the role of matrix metalloproteinases in metastasis

1997 • 1,585 citations

Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3

1996 • 1,555 citations

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

1992 • 1,528 citations

The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA

1991 • 1,375 citations

The Biology of Vascular Endothelial Growth Factor

1997 • 1,203 citations

Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia

1995 • 1,087 citations

Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy

1992 • 1,076 citations

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

1999 • 1,044 citations

Tumor angiogenesis: past, present and the near future

2000 • 973 citations

Important Advances in Oncology

1991 • 768 citations

Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia

1996 • 639 citations

Vascular Endothelial Growth Factor (VEGF)-Mediated Angiogenesis Is Associated with Enhanced Endothelial Cell Survival and Induction of Bcl-2 Expression

1999 • 638 citations

Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity

1998 • 618 citations

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

1984 • 562 citations

The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

1992 • 495 citations

Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian Carcinoma

1995 • 469 citations

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

1998 • 275 citations

Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer.

1993 • 209 citations

Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression.

1994 • 200 citations

Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.

1996 • 183 citations

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1999 • 158 citations

Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer

2000 • 122 citations

Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung

1997 • 121 citations

Antiangiogenic Agents in Cancer Therapy

1999 • 120 citations

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.

1994 • 117 citations

Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.

1999 • 114 citations

Angiogenesis and non-small cell lung cancer

2000 • 103 citations

Matrix metalloproteinase inhibitors: A novel class of anticancer agents

1995 • 98 citations

Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor

1999 • 92 citations

Natural interferon alfa as maintenance therapy for small cell lung cancer

1992 • 82 citations

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.

1995 • 80 citations

Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study.

1998 • 80 citations

VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION AND ANGIOGENESIS IN NONSMALL CELL LUNG CARCINOMAS

1995 • 73 citations

Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma.

1998 • 71 citations

Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.

2001 • 62 citations

Current approaches to targeting cancer using antiangiogenesis therapies

1994 • 54 citations

Antiangiogenic Agents in Cancer Therapy

1998 • 48 citations

Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.

1997 • 47 citations

Association of Expression of Metalloproteinases and Their Inhibitors with the Metastatic Potential of Squamous-Cell Lung Carcinomas

1997 • 43 citations

Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors

1999 • 39 citations

OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF)

1999 • 38 citations

Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer

2000 • 38 citations

Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas

1995 • 24 citations

Cartilage as a Source of Natural Inhibitors of Angiogenesis

1999 • 13 citations

A PHASE II STUDY OF THALIDOMIDE FOR KAPOSI'S SARCOMA

1997 • 12 citations

Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc)

1999 • 11 citations

Pulmonary adenocarcinoma angiogenesis

1997 • 10 citations